Adalimumab combo therapy for esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is at a stage (II to IVA) where surgery is possible and has not spread to distant organs.
- You are between 18 and 75 years old.
- You are physically active enough to do light work (ECOG score 0 or 1).
- You do not have serious heart problems, an active autoimmune disease, or a history of another cancer in the last 5 years.
- You are not pregnant, breastfeeding, or currently being treated for hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding adalimumab (a medicine that helps the immune system) after surgery can prevent esophageal cancer from coming back. It's for people who have already had their cancer completely removed by surgery.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.